1. Home
  2. KRMD vs ENTX Comparison

KRMD vs ENTX Comparison

Compare KRMD & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORU Medical Systems Inc. (DE)

KRMD

KORU Medical Systems Inc. (DE)

N/A

Current Price

$3.00

Market Cap

146.4M

Sector

Health Care

ML Signal

N/A

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

N/A

Current Price

$3.21

Market Cap

147.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRMD
ENTX
Founded
1980
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.4M
147.4M
IPO Year
2019
2015

Fundamental Metrics

Financial Performance
Metric
KRMD
ENTX
Price
$3.00
$3.21
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$6.25
★ $9.75
AVG Volume (30 Days)
165.1K
★ 627.5K
Earning Date
11-10-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 53.85
N/A
EPS
N/A
★ 0.22
Revenue
★ $41,127,366.00
$42,000.00
Revenue This Year
$16.78
N/A
Revenue Next Year
$17.22
N/A
P/E Ratio
★ N/A
$14.05
Revenue Growth
★ 22.23
N/A
52 Week Low
$2.86
$0.91
52 Week High
$6.61
$4.20

Technical Indicators

Market Signals
Indicator
KRMD
ENTX
Relative Strength Index (RSI) 44.58 63.60
Support Level $2.86 $2.64
Resistance Level $3.41 $3.26
Average True Range (ATR) 0.14 0.23
MACD 0.02 0.05
Stochastic Oscillator 34.52 92.73

Price Performance

Historical Comparison
KRMD
ENTX

About KRMD KORU Medical Systems Inc. (DE)

KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: